Tempus AI (NASDAQ:TEM) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Tempus AI (NASDAQ:TEM) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Other research analysts also recently issued reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. TD Cowen reissued a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. HC Wainwright reissued a “buy” rating on shares of Tempus AI in a report on Friday. Finally, Lake Street Capital downgraded Tempus AI to a “hold” rating in a research note on Monday, July 20th. Nine research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Tempus AI currently has a consensus rating of “Hold” and an average target price of $68.92.

Tempus AI Stock Performance

TEM stock opened at $42.69 on Friday. The stock’s 50 day simple moving average is $51.65 and its 200 day simple moving average is $53.56. Tempus AI has a 12-month low of $41.73 and a 12-month high of $104.32. The firm has a market cap of $7.67 billion, a P/E ratio of -24.82 and a beta of 3.46. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm had revenue of $348.12 million during the quarter, compared to the consensus estimate of $345.44 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. The firm’s revenue was up 36.1% on a year-over-year basis. As a group, equities research analysts predict that Tempus AI will post -1.35 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 33,284 shares of the company’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the sale, the chief executive officer directly owned 167,763 shares of the company’s stock, valued at approximately $9,627,918.57. This represents a 16.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James William Rogers sold 11,529 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the transaction, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. This trade represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 616,043 shares of company stock valued at $31,748,593. Corporate insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TEM. Handelsbanken Fonder AB raised its position in Tempus AI by 4.1% in the second quarter. Handelsbanken Fonder AB now owns 32,900 shares of the company’s stock worth $1,906,000 after acquiring an additional 1,300 shares in the last quarter. CoreCap Advisors LLC lifted its holdings in Tempus AI by 293.4% in the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after acquiring an additional 760 shares during the last quarter. NewEdge Advisors LLC boosted its position in shares of Tempus AI by 1.3% during the 1st quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock valued at $1,944,000 after purchasing an additional 536 shares in the last quarter. Avidity Partners Management LP bought a new position in shares of Tempus AI during the 1st quarter valued at about $1,130,000. Finally, Silverback Asset Management LLC grew its stake in shares of Tempus AI by 44.5% in the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock worth $1,614,000 after purchasing an additional 11,000 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.